Beoordelingsverslag van de commissaris aan de Raad van Bestuur – 26 juli 2022 juli 26, 20220OpmerkingenAuditor's Report to the Board of Directors (NL only) Read More
Beoordelingsverslag van de commissaris aan de Raad van Bestuur – 26 juli 2022 juli 26, 20220OpmerkingenAuditor's Report to the Board of Directors (NL only) Read More
Prospectus Nieuwe Aandelen – 19 juli 2022 juli 19, 20220OpmerkingenProspectus voor de toelating tot de handel op Euronext Brussels van maximal 15.651.259 nieuwe aandelen Read More
New Shares Prospectus – July 19, 2022 juli 19, 20220OpmerkingenProspectus for the admission to trading on Euronext Brussels of up to 15,651,259 new shares Read More
Speciaal verslag van de Raad van Bestuur – 18 juli 2022 juli 18, 20220OpmerkingenSpeciaal verslag van de Raad van Bestuur Read More
Board of Directors Special Report – July 18, 2022 juli 18, 20220OpmerkingenSpecial Report of the Board of Directors Read More
Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences juli 11, 20220OpmerkingenEN Read More
Tussentijdse halfjaarresultaten 30 juni 2022 juni 30, 20220OpmerkingenTussentijdse halfjaarresultaten 30 juni 2022 Read More
Interim Financial Report Half-year results as of June 30, 2022 juni 30, 20220OpmerkingenInterim Financial Report Half-year results as of June 30, 2022Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds juni 30, 20220OpmerkingenEN NL Read More
Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting juni 13, 20220OpmerkingenEN Read More
Oxurion Announces Preclinical Presentation on THR-149 at KININ2022 juni 7, 20220OpmerkingenEN Read More
Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting juni 3, 20220OpmerkingenEN Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA mei 31, 20220OpmerkingenEN NL Read More
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 mei 25, 20220OpmerkingenEN NL Read More
Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022 mei 24, 20220OpmerkingenEN Read More
Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) mei 9, 20220OpmerkingenEN NL Read More
Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022 mei 6, 20220OpmerkingenEN NL Read More
